Market research
MYOK MyoKardia, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 12B
- P/E ratio
- Not available
- Analyst target
- 225
- Dividend yield
- 0.0%
- Beta
- 1.83
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US62857M1053
- Market cap
- 12B
- P/E ratio
- Not available
- Analyst target
- 225
- Dividend yield
- 0.0%
- Beta
- 1.83
About
About MyoKardia, Inc
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California. As of November 16, 2020, MyoKardia, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MYOK discussion.
5 years, 4 months ago
MyoKardia, Inc is currently in a long term uptrend where the price is trading 104.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
MyoKardia, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 40.2% to $-85M since the same quarter in the previous year.
Finally, its free cash flow grew by 74.7% to $-31M since the same quarter in the previous year.
Based on the above factors, MyoKardia, Inc gets an overall score of 4/5.